N@N

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry is anticipating a potential recovery in 2025 following a challenging period marked by economic pressures, patent expirations, and regulatory uncertainties. According to a Reuters report, industry leaders are cautiously optimistic about a rebound, driven by the expected launch of new drugs and the potential for increased M&A activity. However, the sector faces significant uncertainty due to the possibility of Donald Trump's return to the presidency, which could lead to policy changes affecting drug pricing, international trade, and healthcare regulations. Trump's previous term saw initiatives like the "most favored nation" pricing model, which aimed to lower drug costs by aligning U.S. prices with those in other countries, causing concern among biopharma companies about future profitability and innovation incentives. Additionally, the industry is grappling with the ongoing effects of the Inflation Reduction Act, which allows Medicare to negotiate drug prices, further complicating the financial landscape for biopharma companies.

Read the Full Reuters Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/biopharma-industry-eyes-2025-bounceback-grapples-with-uncertainty-over-trump-2025-01-14/ ]